Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

Current Opinion in Hematology

Volumn 9, Issue 4, 2002, Pages 303-307

  Gorre, Mercedes E ^a   Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COMPLEMENTARY DNA; GELDANAMYCIN; IMATINIB; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; ZIDOVUDINE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL MODEL; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA; MOUSE; NONHUMAN; NUDE MOUSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE; ANIMAL; DRUG ANTAGONISM; DRUG RESISTANCE; DRUG SCREENING; GENETICS; IN VITRO STUDY; MYELOID LEUKEMIA; PATHOLOGY;

ANIMAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMAN; IN VITRO; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; PIPERAZINES; PROTEIN-TYROSINE KINASE; PYRIMIDINES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; ANIMALS; HUMANS; PROTEIN-TYROSINE KINASES;

EID: 0036014978     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200207000-00007     Document Type: Review

References (31)

1. Chronic myeloid leukemia
2. The biology of chronic myeloid leukemia
3. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration
4. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
5. Acute leukaemia in bcr/abl transgenic mice
6. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
7. Structural mechanism for STI571 inhibition of abelson tyrosine kinase
8. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
9. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
10. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
11. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
12. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
13. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571
14. Alpha(1)-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571
15. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571
16. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
17. Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571
18. Roots of clinical resistance to STI-571 cancer therapy
19. Roots of clinical resistance to STI-571 cancer therapy
20. Point mutations clustered within the ATP binding region of BCR-ABL are common in patients with emerging Gleevec resistance but not in Gleevec non-responsive cases of CML
21. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Gleevec) therapy
22. Resistance to Gleevec: Sequence analysis reveals a spectrum of BCR/ABL kinase domain mutations in both acquired and de novo-resistant cases of CML in myeloid blast crisis
23. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study
24. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
25. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: A gene-expression study
26. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase
27. Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta
28. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl- expressing leukemia cells to cytotoxic chemotherapy
29. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-bl-positive human leukemic blasts
30. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p21 0bcr-abl and v-src proteins before their degradation by the proteasome
31. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)